Ahead of an FDA advisory committee meeting on Grail’s Galleri, additional reporting indicated the agency is providing limited commentary in its materials while still framing questions around clinical validity and performance. The emphasis on briefing documents reinforces how advisory panel preparation can act as a leading indicator of the FDA’s posture. For investors and stakeholders, the key implication remains the downstream reimbursement pathway: approval would improve odds of coverage by Medicare and other payors for the laboratory-based diagnostic that is already commercially available. With the adcom centered on expert interpretation, the FDA’s presentation of evidence and questions is expected to drive both patient expectations and regulatory strategy discussions within the precision oncology diagnostics category.